GlassScriptPhysician profile
Roxana Hazel Ropos
NPI 1437725595
$2,904.28
in general payments reported to CMS, 2019-2025
16 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $185 · 2023: $189 · 2024: $700 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $509.86 | 2023-2024 | Ultomiris |
| Ucb, INC. | $400.97 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $364.27 | 2025 | |
| Janssen Biotech, INC. | $358.92 | 2025 | Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $231.47 | 2022-2024 | Gammagard, Hyqvia |
| Abbvie INC. | $229.74 | 2025 | |
| Amgen INC. | $211.10 | 2024-2025 | Krystexxa, Tavneos, Otezla |
| Radius Health, INC. | $160.21 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $126.23 | 2024 | Fasenra |
| Horizon Therapeutics Plc | $119.33 | 2022-2023 | |
| Glaxosmithkline, LLC. | $66.70 | 2025 | Benlysta |
| Genzyme Corporation | $53.77 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.75 | 2025 | Orencia |
| Fresenius Kabi USA, LLC | $25.18 | 2025 | Tyenne |
| Vifor Pharma, INC. | $17.78 | 2024 | Zemaira |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Ropos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.